About Richard Lalonde
Richard Lalonde is currently an adjunct professor in the Center for Pharmacometrics and Systems Pharmacology in the Department of Pharmaceutics at the University of Florida College of Pharmacy, and a consultant to the pharmaceutical industry. He was previously at Pfizer for 19 years and served as Vice President and Global Head of Clinical Pharmacology for the last 11 years of his tenure, until he retired in 2017. Prior to joining Pfizer via the merger with the Warner Lambert organization, he was Scientific Director and Head of Clinical Pharmacology and Pharmacokinetics at Phoenix International in Montreal from 1991 to 1998. From 1984 to 1991 he was Assistant Professor and then a tenured Associate Professor and Vice Chair for Research in the Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee, Memphis. He also worked from 1980 to 1984 at the University of Ottawa Health Sciences Centre. Richard is a Fellow of the American College of Clinical Pharmacology, the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacy. He was President of the American Society for Clinical Pharmacology and Therapeutics (2011 – 2012), a member of its Board of Directors (2010-2013) and in 2017 received the Gary Neil Prize for Innovation in Drug Development from ASCPT. Richard also received the International Society of Pharmacometrics Leadership Award in 2014. From 2004 – 2009 he served on the Board of Regents of the American College of Clinical Pharmacology. He has been a member of the editorial board of Clinical Pharmacology and Therapeutics since 2005 (Associate Editor 2007-2010) and was a member of the editorial board of Pharmaceutical Research from 1998 – 2001. He served on the National Advisory General Medical Sciences Council at the National Institutes of Health, Bethesda, MD from 2013 – 2016. Richard has been an invited speaker at various national and international meetings of professional societies, universities, and governmental/regulatory agencies in the US (FDA & NIH), Europe (EMA), Japan (PMDA) and China (CFDA). Over the past 39 years, his work has been focused on the quantitative application of pharmacokinetic and pharmacodynamic principles to the optimal development and utilization of new drugs in patients. Richard is a graduate of the University of Minnesota (Pharm.D.) and the University of Toronto (B.Sc. Pharmacy).